Middle East Cancer Diagnostics Market Size, Growth, and Forecast 2026-2034

Market Overview

The Middle East cancer diagnostics market size reached USD 9,872.4 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 18,108.9 Million by 2034, exhibiting a growth rate (CAGR) of 6.97% during 2026-2034. Advancing medical technologies drive demand for early detection tools across regional healthcare systems. Growing awareness and improved infrastructure support widespread adoption of innovative screening methods, enhancing patient outcomes and supporting oncology care advancements throughout the area.

How AI is Reshaping the Future of Middle East Cancer Diagnostics Market:

• Lunit’s AI tools now power Qatar’s national breast screening, helping catch cancers earlier and cut missed diagnoses across the program.

• Saudi hospitals partner with Lunit to roll out AI chest X-ray analysis, speeding lung cancer detection for thousands of patients daily.

• UAE clinics use AI-driven pathology systems that flag prostate cancer signs in tissue samples with higher precision than traditional reviews alone.

• Government-backed digital health drives across the Gulf push AI diagnostics into public hospitals, making advanced cancer screening far more accessible.

• Regional oncology centers report AI cuts image-reading times sharply while lifting detection accuracy for common cancers like breast and lung.

Grab a sample PDF of this report: https://www.imarcgroup.com/middle-east-cancer-diagnostics-market/requestsample

Market Growth Factors

The rising incidence of cancer across the Middle East, driven by aging populations, lifestyle shifts including dietary changes and tobacco use, and greater environmental exposures, is significantly boosting demand for advanced diagnostic solutions. Heightened public awareness campaigns and expanding screening initiatives are encouraging earlier detection, prompting healthcare providers to adopt more sophisticated testing methods that improve patient outcomes and support timely clinical decision-making throughout the region.

Technological progress in molecular diagnostics, liquid biopsy techniques, genomic profiling, and digital pathology is transforming cancer detection capabilities in the Middle East. These innovations enable more precise identification of biomarkers and tumor characteristics, facilitating personalized treatment approaches. Growing clinician confidence in these tools, combined with improving laboratory infrastructure, is accelerating their integration into routine clinical practice and elevating overall diagnostic accuracy and efficiency.

Government-led healthcare reforms and substantial investments in medical infrastructure are key drivers supporting the cancer diagnostics landscape. National strategies focused on non-communicable diseases are expanding access to specialized oncology centers and promoting the adoption of modern diagnostic technologies. Collaborative efforts between public institutions and private stakeholders are further strengthening capacity, enhancing service availability, and fostering an environment conducive to continuous improvement in cancer care delivery.

Market Segmentation

Product Insights:

• Consumables

  • Antibodies

  • Kits and Reagents

  • Probes

  • Others

• Instruments

  • Pathology-Based Instruments

  • Imaging Instruments

  • Biopsy Instruments

Technology Insights:

• IVD Testing

  • Polymerase Chain Reaction (PCR)

  • In Situ Hybridization (ISH)

  • Immunohistochemistry (IHC)

  • Next-Generation Sequencing (NGS)

  • Microarrays

  • Flow Cytometry

  • Immunoassays

  • Others

• Imaging

  • Magnetic Resonance Imaging (MRI)

  • Computed Tomography (CT)

  • Positron Emission Tomography (PET)

  • Mammography

  • Ultrasound

• Biopsy Technique

Recent Development & News

Application Insights:

• Breast Cancer

• Lung Cancer

• Colorectal Cancer

• Melanoma

• Others

End User Insights:

• Hospitals and Clinics

• Diagnostic Laboratories

• Others

Country Insights:

• Saudi Arabia

• Turkey

• Israel

• United Arab Emirates

• Iran

• Iraq

• Qatar

• Kuwait

• Oman

• Jordan

• Bahrain

• Others

Recent Development & News

• June 2026: M42’s National Reference Laboratory partners with Qritive to introduce AI-powered prostate cancer diagnostics in the UAE, integrating digital pathology analysis at Cleveland Clinic Abu Dhabi to highlight suspicious findings, standardize grading per ISUP criteria, and support faster, more consistent detection amid rising regional cases.

• June 2026: KAUST researchers unveil a stain-free imaging platform using engineered silicon slides for colorectal and other tissue samples, achieving 99% agreement with conventional pathology assessments across 120 patients while cutting sample preparation time by approximately 40-50% to enable more consistent AI-assisted cancer diagnostics.

• July 2026: M42’s National Reference Laboratory and Abbott launch a strategic partnership in the UAE to deploy innovative early cancer detection solutions based on biomarker testing and multi-marker algorithm-driven analyses, beginning with a pilot programme to strengthen earlier identification and clinical decision-making under national cancer control priorities.

Customization Note:

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302